Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Inclusion criteria: 1. patient over 20 years old with depression diagnosed by a psychiatrist
and MADRS >= 25 scores; 2. failed to improve by at least optimal dosage of two
antidepressants for four weeks and one psychotherapy. Patients and outcome assessors will be
blinded from intervention the patients have.
Participants will be randomized into two groups that are intervention (ketamine 0.5 mg/kg IV
drip in 40 minutes) and control (midazolam 0.045 mg/kg IV drip in 40 minutes) groups.
Participants will administer ketamine/midazolam once daily for three consecutive days. They
will be evaluate MADRS changing, vital signs, dissociative symptoms, CGI, and quality of life
(EQ-5D-5L) during the treatment, at 1 week and 4 weeks after treatment completion.